神经钙黏蛋白(NCAD)重组蛋白
Recombinant N-cadherin (NCAD)
CDw325; CD325; CDHN; CDH2; Cadherin 2 Type 1; N-Cadherin
- 编号RPB481Hu01
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位细胞膜
- 预测分子量27.1kDa
- 实际分子量27kDa(差异分析请参阅说明书)
- 片段与标签His50~Val276 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 97%
- 等电点6.4
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 984 ¥ 2460 ¥ 4920 ¥ 14760 ¥ 36900
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
RPB481Hu02 | 神经钙黏蛋白(NCAD)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB481Hu01 | 神经钙黏蛋白(NCAD)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB481Hu01 | 神经钙黏蛋白(NCAD)多克隆抗体 | WB; IHC; ICC; IP. |
PAB481Hu02 | 神经钙黏蛋白(NCAD)多克隆抗体 | WB; IHC; ICC; IP. |
LAB481Hu71 | 神经钙黏蛋白(NCAD)多克隆抗体(生物素标记) | WB; IHC; ICC. |
MAB481Hu22 | 神经钙黏蛋白(NCAD)单克隆抗体 | WB; IHC; ICC; IP. |
SEB481Hu | 神经钙黏蛋白(NCAD)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB481Hu | 神经钙黏蛋白(NCAD)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. [Pubmed: 23830989] |
British journal of haematology | Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. [Pubmed: 23438504] |
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY | Elevated Cerebrospinal Fluid and Plasma N-Cadherin in Alzheimer Disease [Pubmed: 32296844] |
Cell Biol Toxicol | ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer [33566221] |
CELL BIOLOGY AND TOXICOLOGY | Metastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence [33758996] |
Pharmacol Res | DOC2B is a Negative Regulator of Wnt/β-catenin Signaling Pathway in Cervical Cancer [Pubmed:35500882] |
留言咨询